SPOTLIGHT: Elan touts new Tysabri data

Elan says that new trial data for Tysabri not only demonstrated a significant reduction in symptoms of multiple sclerosis but also was linked to improvements in the quality of life of patients. Elan and Biogen Idec are currently awaiting a final decision on Tysabri by the FDA. Report